Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects
Tóm tắt
Từ khóa
Tài liệu tham khảo
Trost W., Halbach G. (1978): Anti-phalloidine and alphaamanitine action of silybin in comparison with compounds similar to structural parts of silybin. Experientia 34, 1051–1052.
Conti M., Malandrino S., Magistretti M.J. (1989): Liver protective activity of IdB 1016, a new flavanolignan complex. 3rd International Symposium on Flavonoids in Biology and Medicine, Singapore, 13–17 November 1989, Abstract_P29.
Morazzoni P., Magistretti M.J., Zanolo G., Poletti P. (1989): Comparative bioavailability of IdB 1016, a new flavanoügnan complex, in rats. 37th Annual Congress on Medicinal Plant Research, Braunschweig, 5–9 September 1989, Abstract P2–P24.
Gabetta E., Bombardelli E., Pifferi G. US Patent 4, 754, 508.
Gabetta B., Zini G.F., Pifferi G. (1989): Spectroscopic studies on IdB 1016, a new flavanolignan complex. 37th Annual Congress on Medicinal Plant Research, Braunschweig, 5–9 September 1989, Abstract P1–P38.
Martinelli E.M., Morazzoni P., Livio S., Uberti E. (1991): Determination of silybin in human plasma and urine by HPLC. Submitted.
Lorenz D., Lucker P.W., Mennicke W.H., Wetzelaberger N. (1984): Pharmacokinetic studies with Silymarin in human serum and bile. Meth. Find. Exp. Clin. Pharmacol. 6, 655–661.
Zanolo G. Pilot studies of IdB 1016 with plasma level determinations in normal volunteers. R.B.M. Exp. N. 254, Inverni della Beffa S.p.A., Data on file.
Livio S., Seghizzi R., Pifferi G. (1990): Diffusion of IdB 1016 across artificial and biological membranes. 4th European Congress of Biopharmaceutics and Pharmacokinetics, Geneva, 17–19 April 1990.
Cavallini L., Lucchetti G. (1976): Considerazioni clinicofarmacologiche sulla silimarina. Gazz. Med. It. 135, 365–374.
Terragna A. Tolerability of IdB 1016 after repeated oral administration in normal subjects. Study Report 3/89/FC, Inverni della Beffa, S.p.A. Data on file.
Flory P.J., Krug G., Lorenz D., Mennicke W.H. (1980) Untersuchungen zur Elimination von Silymarin bei cholezystektomierten Patienten. 1. Mitteilung: Biliare und renale Elimination nach einmaliger oraler Gabe. Planta Medica 38, 227–237.